Seven Bridges
Seven Bridges (now part of Velsera) is a cloud-native bioinformatics platform company serving biopharma, government, and academic institutions with genomic and clinical data analysis tools, federated datasets, and workflow automation on AWS and Google Cloud.
- Company typePrivate
- Founded2009
- HeadquartersCharlestown, United States
- Headcount251–500
- GTM typeB2B
- OfferingSoftware
What Seven Bridges does
Seven Bridges Genomics Inc. is a privately held cloud-native bioinformatics company (now operating as part of Summa Equity-backed Velsera, formed January 12, 2023) that provides a biomedical data analysis platform serving biopharma R&D, government research agencies, academic institutions, clinical diagnostic labs, and patient advocacy organizations. The company's core product is the Seven Bridges Platform — a multi-cloud environment (AWS US, AWS EU Frankfurt, Google Cloud Platform) that supports CWL, WDL, and Nextflow workflows, Docker-based app execution via the Seven Bridges Image Registry, hosted JupyterLab and RStudio interactive analysis (Data Studio), and federated data access via GA4GH DRS-compatible interfaces. Layered on top of the platform are three specialized commercial products: GRAF (graph-based pangenome variant detection recognized as one of the most accurate INDEL callers globally), ARIA (population-scale clinico-genomic data analytics on a Snowflake data warehouse, commercially launched October 2021), and RHEO (push-button multi-omic workflow automation). The company also operates the Cancer Genomics Cloud (CGC) under NCI, hosting GDC, PDC, CDS, ICDC, and TCIA datasets.
The business model combines platform subscription and enterprise licensing (quote-based annual contracts with SSO, Divisions, and centralized billing), usage-based cloud compute and storage consumption (AWS EC2/S3 and GCP Compute Engine/GCS metered billing), professional and scientific services for biopharma and government deployments (e.g., PanCAN, NCI, UK Biobank, CareDx), managed hybrid on-premise/cloud deployments for clinical diagnostics customers, and data licensing for commercial access to ARIA-curated clinico-genomic datasets. Free academic licensing of GRAF serves as a top-of-funnel land-and-expand motion. Go-to-market is enterprise field sales with named-account targeting (Pfizer, BMS, Becton Dickinson, CareDx, DDL, NCI, UK Biobank, VA Million Veteran Program), supplemented by channel partnerships with AWS, Google Cloud, and ZS Associates. The company holds SOC 2 Type 2, SOC 3, HIPAA, ISO 27001/27017/27018, FISMA, GDPR, FDA 21 CFR Part 11, CLIA, CAP, and dbGaP Security Best Practices certifications — a compliance posture that treats all genomic data as PHI by default and serves as a primary procurement enabler for regulated buyers. Revenue and ARR are not publicly disclosed; the company has raised approximately $98 million in disclosed funding across a $3M early round (Sept 2014), $45M Series A (Feb 2016, led by Kryssen Capital), a Series B (April 2018), and a Series C initial close (April 2021), with the Series C investor undisclosed.
Seven Bridges firmographics
Firmographics- Name
- Seven Bridges
- Legal name
- Seven Bridges Genomics Inc.
- Website
- https://sevenbridges.com
- Company type
- Private
- Founded year
- 2009
- Operating status
- Operating
- Headcount range
- 251–500 employees
- Short description
- Seven Bridges (now part of Velsera) is a cloud-native bioinformatics platform company serving biopharma, government, and academic institutions with genomic and clinical data analysis tools, federated datasets, and workflow automation on AWS and Google Cloud.
- Ownership category
- akta.pro rank
Seven Bridges industry classification
Industry- Product category
- Bioinformatics Software
- NAICS
- Scientific Research and Development Services (5417), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Computer Systems Design and Related Services (54151), Custom Computer Programming Services (541511)
- SIC
- Services-Commercial Physical & Biological Research (8731), Services-Prepackaged Software (7372), Services-Computer Programming Services (7371)
- akta.pro primary industry
- Scientific Data Management & Data Platforms (SDMS/Data Lakehouse for R&D) (HLAGAJAC)
- akta.pro secondary industries
- AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO), Healthcare Data Lakes, Lakehouses & Cloud Warehouses (HLACAIAA), Bioinformatics, Multi-Omics Data Analysis & Interpretation Services (HLAGANAI), Clinical Trial Informatics (EDC/CTMS/eCOA/eTMF) (HLAGAJAM)
Keywords
Where Seven Bridges is headquartered
LocationHeadquarters
- HQ city
- Charlestown
- HQ country
- United States
- HQ region
- North America
Offices6 records
Markets served
Seven Bridges business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Revenue model
- Platform Subscription & Enterprise Licensing: Recurring platform access for enterprise customers (biopharma, government, academic institutions) with Enterprise feature tiers including Divisions, teams, centralized billing, and SSO. Enterprise features are gated behind organizational subscription agreements.
- Cloud Compute & Storage Consumption: Usage-based billing for AWS S3/GCS storage (incl. discounted archiving tier), EC2/Google Compute Engine instances, spot instance usage, and data transfer. Costs are tracked per project/billing group and visible on the Payments page.
- Professional & Scientific Services: Custom bioinformatic services including end-to-end multi-omic data analysis, workflow development, and on-demand expert scientific support ("Meet our scientists" engagement model). Used in deployments with PanCAN, NCI, UK Biobank, and biopharma customers.
- Managed Services (Hybrid Deployments): Managed deployment model where Seven Bridges integrates its platform/automation with on-premise customer sequencers and environments (e.g., CareDx AlloSure 3.0 deployment) with minimal human intervention, reducing customer operational burden.
- Data Licensing / Federated Data Access (ARIA, GRAF): Commercial access to curated population-scale clinico-genomic datasets via ARIA, plus free academic licensing of GRAF Germline Variant Detection Workflow and GRAF Pan Genome Reference (a marketing-led land-and-expand strategy into academic accounts).
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Subscription | Annual | Platform access: Request Access / quote-based enterprise license |
| Usage-based | Pay-as-you-go | Cloud infrastructure consumption: per-resource metered pricing |
| Freemium | Pay-as-you-go | Free academic tier for GRAF Workflows |
Go-to-market motion4 records
Distribution channels5 records
Marketing channels9 records
Seven Bridges product offering
Product offeringCore offering
Seven Bridges builds and operates a cloud-native bioinformatics platform that enables researchers and organizations to organize, explore, and run genomic, multi-omic, and clinical-genomic data analyses at scale using CWL, WDL, and Nextflow workflows on AWS and Google Cloud. On top of the core platform, the company sells specialized products including ARIA (population-scale clinico-genomic data analytics), GRAF (pan-genome graph-based variant analysis), RHEO (workflow automation), and the Cancer Genomics Cloud, complemented by professional scientific services and managed hybrid deployments for biopharma, government, and academic customers.
Product overview
Seven Bridges is a platform-plus-modules architecture: the core offering is the Seven Bridges Platform — a cloud-based bioinformatics environment where researchers build and run workflows (CWL, WDL, Nextflow), attach cloud storage volumes, host Docker apps via the Seven Bridges Image Registry, and analyze data in Data Studio's hosted JupyterLab/RStudio instances. On top of this core platform, Seven Bridges sells several specialized modules and sub-brands: ARIA adds population-scale clinico-genomic data analytics (built on Snowflake), GRAF provides graph-based genome analysis using pangenome references, and RHEO delivers workflow automation and SDKs for production pipelines. Sister offerings include the Cancer Genomics Cloud (CGC), an NCI-flavored instance of the platform for cancer research, and the Unified Patient Network, a clinical-molecular data network for translational research.
Differentiator
Problem solved
Functional benefit
Brands
- Seven Bridges Platform: Core cloud-based bioinformatics ecosystem enabling genomic and phenotypic data analysis with workflow automation, collaboration, and security features.
- ARIA
- GRAF
- RHEO
- Velsera
Products and services
- Seven Bridges Platform Cloud-based bioinformatics platform that enables researchers and organizations to organize, explore, and run omics data analyses through a unified environment supporting CWL, WDL, and Nextflow workflows, public and private apps, cloud storage volumes, project collaboration, and hosted JupyterLab/RStudio Data Studio instances. Targeted at biopharma R&D, government research programs, academic institutions, and clinical laboratories.
- ARIA Population-scale clinico-genomic data analysis platform built on a Snowflake data warehouse that unlocks federated clinical-genomic datasets and integrates them with research workflows to support accelerated drug discovery for biopharma and healthcare enterprises.
- GRAF (Genome Representation and Analysis Framework) Pan-genome graph-based genome analysis engine that transforms the linear human genome reference into a genome graph, enabling large human population studies, rare disease studies using curated mutation graphs, precise de novo mutation detection via family genome graphs, and sensitive somatic mutation detection in tumors; available free for academic researchers under commercial licensing.
- RHEO (Workflow Automation) Push-button multi-omic workflow automation framework that captures the entire flow from data ingress to final results, supporting visual interface (GUI), CLI, and API management with features including parallelization, conditionals, loops, and TypeScript-based automation definitions. Targeted at bioinformatics and production pipeline teams.
- Cancer Genomics Cloud (CGC) Cloud platform powered by Seven Bridges that hosts NIH/NCI cancer datasets (GDC, PDC, CDS, ICDC, TCIA) with two-tiered Open and Controlled access, integrated via DRS server with the Seven Bridges Platform; targeted at NCI-funded cancer researchers and consortia.
- Unified Patient Network Network product that aggregates clinical and molecular data across healthcare providers, enabling translational research and precision medicine initiatives on a harmonized dataset; targeted at biopharma R&D and healthcare enterprises.
- Professional and Scientific Bioinformatics Services Custom bioinformatic services including end-to-end multi-omic data analysis, workflow development, on-demand expert scientific support, and managed hybrid cloud/on-premise deployments (e.g., CareDx AlloSure 3.0) delivered by Seven Bridges scientists to biopharma, government, and academic customers.
Quantifiable outcome
- Dramatically reduced time to results for clinical workflows (CareDx AlloSure 3.0 turnaround requirements met through workflow automation)
- +3 more outcomes
Companies that use Seven Bridges
Customer profileNamed customers21 records
Segments5 records
Ideal customer profiles4 records
Seven Bridges technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- Yes
- API docs
- API detail
Core technology
AI maturity
App detail
Integration8 records
Feature10 records
Seven Bridges partnerships and signals
Strategic signalPartnerships
15 partnerships are on record, tiered major (international academic collaboration), core (federal subcontractor), major (consulting channel), core (flagship nonprofit partner), core (flagship customer-partner), flagship (national genomics), minor (specialty co-marketing), major (academic consortium), minor (technology partnership), major (federal initiative), major (federal program), flagship (founding government program), minor (early technology partnership) and flagship (core cloud infrastructure).
- University of São Paulomajor (international academic collaboration)Seven Bridges collaborated with the University of São Paulo and Google Cloud to build a Brazilian Reference Genome, combining academic expertise, cloud infrastructure, and Seven Bridges' bioinformatics platform.
- Scripps Researchcore (federal subcontractor)Selected along with Scripps Research to develop the data ecosystem for the National Institute of Allergy and Infectious Diseases (NIAID). Joint development of a federated data infrastructure for infectious disease research.
- ZS Associatesmajor (consulting channel)ZS Associates and Seven Bridges partnered to innovate drug research and propel precision medicine. The alliance combines ZS's commercial life sciences consulting footprint with Seven Bridges' bioinformatics platform.
- Pancreatic Cancer Action Network (PanCAN)core (flagship nonprofit partner)Seven Bridges was selected by PanCAN to build a customized, integrated health data platform for pancreatic cancer research, providing researchers access to PanCAN's longitudinal clinical, genetic, and outcome data. Project goal is to evolve the data sharing paradigm and bring data from ongoing clinical trials to the research community.
- CareDxcore (flagship customer-partner)Seven Bridges announced a partnership with CareDx, Inc. (Nasdaq: CDNA) supporting the AlloSure 3.0 workflow for non-invasive kidney transplant rejection testing. Seven Bridges Platform and Automation products integrate with CareDx's on-premise sequencer and environment using a 'hybrid' automation method. Quoted: Bill Moss, CEO, Seven Bridges, called this a 'strategic scientific and bioinformatics partner' relationship.
- UK Biobankflagship (national genomics)Seven Bridges was selected as the core informatics supplier for the UK Biobank Vanguard Phase, deploying the bioinformatics platform to support population-scale genomics research on UK Biobank data.
- e-NIOSminor (specialty co-marketing)Seven Bridges & e-NIOS partnership to break the biomarker bottleneck by combining e-NIOS's clinical biomarker capabilities with Seven Bridges' bioinformatics platform and data infrastructure.
- The Jackson Laboratorymajor (academic consortium)The Jackson Laboratory and Seven Bridges collaborated to build a centralized data platform to advance cancer research, aggregating and analyzing cancer-related datasets on the Seven Bridges platform.
- Spatial Transcriptomicsminor (technology partnership)Seven Bridges announced a strategic partnership with Spatial Transcriptomics to integrate spatial transcriptomics capabilities into the Seven Bridges bioinformatics ecosystem.
- Cancer Moonshot Initiativemajor (federal initiative)Seven Bridges joined the Cancer Moonshot Initiative on October 17, 2016 with a cloud platform to speed blood profiling research, and was selected to develop a Pediatrics data platform announced at the White House Precision Medicine Initiative on February 25, 2016.
- U.S. Department of Veterans Affairs - Million Veteran Programmajor (federal program)The U.S. Department of Veterans Affairs collaborated with Seven Bridges to power Million Veteran Program research projects, leveraging the platform for VA-scale genomics analysis.
- National Cancer Institute (NCI)flagship (founding government program)Seven Bridges was selected by NCI on October 21, 2014 to develop the Cancer Genomics Cloud (CGC) pilot. NCI extended the scope of the pilot on October 27, 2016. The CGC hosts the Genomic Data Commons (GDC), Proteomic Data Commons (PDC), Cancer Data Service (CDS), Integrated Canine Data Commons (ICDC), and The Cancer Imaging Archive (TCIA), and is positioned as a flagship federated data ecosystem partnership.
- Cellular Researchminor (early technology partnership)Cellular Research and Seven Bridges partnered to offer RNA-Seq products, combining Cellular Research's assay technology with Seven Bridges' cloud bioinformatics analysis.
- Amazon Web Services (AWS)flagship (core cloud infrastructure)AWS is the primary underlying IaaS for the Seven Bridges Platform. Resources used include S3 for storage and EC2 for on-demand compute. Seven Bridges has been offering genomic data processing on the AWS cloud since early 2012, processes Petabytes of data for thousands of users, holds a BAA with AWS, and runs the platform on AWS US and AWS EU (Frankfurt) regions.
- Google Cloud Platform (GCP)flagship (core cloud infrastructure)Google Cloud is the secondary underlying IaaS for the Seven Bridges Platform. Resources used include Google Cloud Storage (GCS) for encrypted storage and Google Compute Engine instances. Seven Bridges Platform came to Google Cloud Platform on January 19, 2016 for multi- and hybrid-cloud support.
Scale indicators10 records
Recent moves9 records
Expansion highlights6 records
Seven Bridges competitors and assessment
Company assessmentBroad incumbents
- Google Cloud Life Sciences / Cloud Healthcare API: Google Cloud's managed services for genomics pipelines and healthcare data interoperability. Comparable technical capabilities to portions of Seven Bridges' platform, with the distribution advantage of being native to the underlying cloud provider.
- Amazon Web Services HealthOmics: AWS-native managed bioinformatics service for genomics workflows and data. Comparable in workflow execution but built directly into the AWS substrate on which Seven Bridges runs, representing both a partner and a long-term competitive threat.
- Illumina (BaseSpace Sequence Hub, DRAGEN): Sequencer vendor offering secondary analysis (DRAGEN) and cloud bioinformatics (BaseSpace) bundled with its sequencing instruments. Competes with Seven Bridges on downstream bioinformatics, with significant distribution leverage from installed sequencer base.
- QIAGEN Digital Insights (formerly QIAGEN Bioinformatics): Established bioinformatics portfolio (CLC bio, Ingenuity Pathway Analysis, QIAseq) embedded within a major life-sciences tools provider. Competes with Seven Bridges in genomic analysis tools, though distributed as part of a wider wet-lab-to-software stack rather than a pure cloud bioinformatics platform.
Direct peers
- BC Platforms: Genomics and clinical data platform offering federated data access, bioinformatic workflow execution, and population genomics services to pharma, healthcare, and national genomics programs. Comparable to Seven Bridges' ARIA in particular.
- DNAnexus: Cloud-based biomedical informatics platform serving biopharma, clinical diagnostics, and federal genomics customers (including NIH). Direct competitor offering similar genomics workflow execution, multi-cloud architecture, and regulated-environment compliance.
- Lifebit Biotech: Cloud genomics and bioinformatics platform with federated data access (Lifebit CloudOS) serving national genomics programs (e.g., Genomics England) and biopharma. Direct competitor in the federated genomics infrastructure category.
- Terra.bio (Broad Institute / Verily): Cloud genomics workspace co-developed by the Broad Institute and Verily on Google Cloud, serving NIH-funded researchers and consortia. Closely comparable to Seven Bridges' Cancer Genomics Cloud in target customer (NIH/NCI) and workflow execution model.
Emerging players
- Partek (now part of Illumina): Genomic and multi-omic analysis software (Partek Flow, Partek Genomics Suite) used by academic and translational researchers. Comparable in single-cell and bulk RNA-seq analysis workflows that overlap with Seven Bridges' core platform capabilities.
- SOPHiA GENETICS: Clinical genomics platform combining NGS analytics, interpretation, and a federated hospital network. Comparable to Seven Bridges' clinical genomics / CareDx-style deployments, but with stronger focus on routine clinical reporting.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks6 records
Key highlights7 records
Customer concentration
Seven Bridges social profiles
Digital presenceSeven Bridges compliance and trust
Trust signalCompliance12 records
Seven Bridges financial estimates
Financial estimateRevenue estimate
Valuation estimate
Seven Bridges leadership team
Management profileNumber of profiles
Profiles9 records
Seven Bridges subsidiaries and ownership
Company hierarchySubsidiaries3 records
Seven Bridges funding detail
Funding detailFunding overview
Funding rounds4 records
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Seven Bridges M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Seven Bridges
What does Seven Bridges do?
Seven Bridges builds and operates a cloud-native bioinformatics platform that enables researchers and organizations to organize, explore, and run genomic, multi-omic, and clinical-genomic data analyses at scale using CWL, WDL, and Nextflow workflows on AWS and Google Cloud. On top of the core platform, the company sells specialized products including ARIA (population-scale clinico-genomic data analytics), GRAF (pan-genome graph-based variant analysis), RHEO (workflow automation), and the Cancer Genomics Cloud, complemented by professional scientific services and managed hybrid deployments for biopharma, government, and academic customers.
Is Seven Bridges a public or private company?
Seven Bridges is a private company. It is classified as private equity controlled and is currently operating.
When was Seven Bridges founded?
Seven Bridges was founded in 2009. It employs 251 to 500 people.
Where is Seven Bridges based?
Seven Bridges is headquartered in Charlestown, United States, in the North America region.
How does Seven Bridges make money?
Five revenue lines are on record. Platform Subscription & Enterprise Licensing is the primary driver. The others are cloud Compute & Storage Consumption, professional & Scientific Services, managed Services (Hybrid Deployments) and data Licensing / Federated Data Access (ARIA, GRAF).
Who are Seven Bridges's main competitors?
Broad incumbents on record are Google Cloud Life Sciences / Cloud Healthcare API, Amazon Web Services HealthOmics, Illumina (BaseSpace Sequence Hub, DRAGEN) and QIAGEN Digital Insights (formerly QIAGEN Bioinformatics). Direct peers are BC Platforms, DNAnexus, Lifebit Biotech and Terra.bio (Broad Institute / Verily). Emerging players are Partek (now part of Illumina) and SOPHiA GENETICS.
Does Seven Bridges have an API?
Yes. Seven Bridges provides a public REST API that lets developers programmatically manage bioinformatics projects, apps, files, tasks, and volumes. The platform supports authentication via authentication token, and exposes libraries/SDKs in Python, R, and Java, plus a Command Line Interface (CLI). A documented API rate limit applies. Developer documentation is at docs.sevenbridges.com/docs/the-api.
What industry is Seven Bridges in?
Seven Bridges's product category is Bioinformatics Software. Its primary akta.pro industry code is HLAGAJAC, Scientific Data Management & Data Platforms (SDMS/Data Lakehouse for R&D), with a secondary code of HLAGAJAO, AI/ML Platforms for Drug Discovery & Experiment Optimization. Its NAICS code is 5417 and its SIC code is 8731.